This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Inoue, T. Articles by Morooka, S. Search for Related Content PubMed PubMed Citation Articles by Inoue, T. Articles by Morooka, S.

CLINICAL STUDY: CORONARY ARTERY DISEASE

Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease

^a Department of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine, Koshigaya, Saitama, Japan

Manuscript received September 25, 2000; revised manuscript received January 23, 2001, accepted February 6, 2001.

Reprint requests and correspondence: Dr. Teruo Inoue, Department of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine, 2-1-50 Minamikoshigaya, Koshigaya City, Saitama 343-8555, Japan
inouet{at}dokkyomed.ac.jp

OBJECTIVES

This study aimed to elucidate whether an antibody against oxidized low density lipoprotein (anti-Ox-LDL) could predict short-term coronary artery atherosclerotic lesion progression.

BACKGROUND

It is still controversial whether higher levels of the anti-Ox-LDL titer are associated with atherosclerotic coronary artery disease.

METHODS

In 52 patients undergoing coronary angioplasty and six-month follow-up angiography, we performed quantitative coronary angiographic analysis of a lesion on a branch away from the intervention site vessel and assessed lesion progression or regression using the Progression-Regression score calculated as the baseline minimal lumen diameter minus the follow-up minimal lumen diameter. The serum anti-Ox-LDL titer was measured using an enzyme-linked immunosorbent assay method just before the initial angiography in all patients.

RESULTS

The anti-Ox-LDL titer was 16.6 ± 1.5 AcU/ml in the progression group (Progression-Regression score >0.15 mm; n = 20), which was significantly higher (p < 0.001) than the value of 9.5 ± 1.2 in the regression group (–0.15 mm; n = 14) and also higher (p < 0.01) than the value of 11.4 ± 1.3 in the no-change group (–0.15 to 0.15 mm; n = 18). The Progression-Regression score was correlated with the antibody titer in all patients (r = 0.56, p < 0.001). Multiple regression analysis showed that the Progression-Regression score was independently correlated with the antibody titer (r = 0.44, p < 0.01) as well as lipoprotein (a) (r = 0.33, p < 0.05).

CONCLUSIONS

Anti-Ox-LDL may be an independent predictor of coronary atherosclerotic lesion progression in the short term.

Abbreviations and Acronyms   AMI = acute myocardial infarction   ANOVA = analysis of variance   anti-Ox-LDL = antibody against oxidized low density lipoprotein   apo = apolipoprotein   ELISA = enzyme-linked immunosorbent assay   LDL = low density lipoprotein   Lp(a) = lipoprotein(a)   MDA = malonic dialdehyde   RLP = remnant-like lipoprotein particle

This article has been cited by other articles:

				G. N. Fredrikson, G. Berglund, R. Alm, J.-A. Nilsson, P. K. Shah, and J. Nilsson Identification of autoantibodies in human plasma recognizing an apoB-100 LDL receptor binding site peptide J. Lipid Res., September 1, 2006; 47(9): 2049 - 2054. [Abstract] [Full Text] [PDF]

				F Violi, L Loffredo, L Musella, and A Marcoccia Should antioxidant status be considered in interventional trials with antioxidants? Heart, June 1, 2004; 90(6): 598 - 602. [Abstract] [Full Text] [PDF]

				J. Frohlich and M. Dobiasova Fractional Esterification Rate of Cholesterol and Ratio of Triglycerides to HDL-Cholesterol Are Powerful Predictors of Positive Findings on Coronary Angiography Clin. Chem., November 1, 2003; 49(11): 1873 - 1880. [Abstract] [Full Text] [PDF]